Designed multiple ligands in metabolic disease research: from concept to platform.

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease, and drug monotherapy typically results in unsatisfactory treatment outcomes for patients. Even when used in combination, existing therapies lack efficacy in the long term. Designed multiple ligands (DMLs) are compounds developed to modulate multiple targets relevant to a disease. DMLs offer the potential to yield greater efficacy over monotherapies, either by modulating different biological pathways, or by boosting a single one. However, examples of DMLs progressing into clinical trials, or onto the market are rare; DML drug discovery is challenging, and perceived by some to be almost impossible. Nevertheless, with the judicious selection of biological targets, both from a biological and chemical perspective, it is possible to develop drug-like DMLs.

• Authors: W Gattrell, C Johnstone, S Patel, C Sambrook Smith, A Scheel, M Schindler
• Journal: Drug discovery today (Drug Discov Today) Vol. 18 Issue 15-16 Pg. 692-6 (Aug 2013) ISSN: 1878-5832 [Electronic] England
• PMID: 23454344 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Ligands

Topics

• Animals
• Diabetes Mellitus, Type 2 (drug therapy, metabolism)
• Dipeptidyl-Peptidase IV Inhibitors (administration & dosage, chemistry, metabolism)
• Drug Design
• Humans
• Ligands
• Metabolic Diseases (drug therapy, metabolism)